新規登録 | ログイン | FAQ      [?] 

タグ: oncology [118 articles]

Recent papers classified by the tag oncology.
  • Intrahospital supervised exercise training: a complementary tool in the therapeutic armamentarium against childhood leukemia
    Leukemia, Vol. aop, No. current.
    by A Lucia, M Ramírez, AFS San Juan, SJ Fleck, J García-Castro, L Madero, L Madero
    posted to activity leukemia oncology paediatric physical by zonbubob on 2008-02-15 12:06:25 as read
  • Challenges and opportunities for in vivo imaging in oncology.
    Technol Cancer Res Treat, Vol. 1, No. 6. (December 2002), pp. 419-422.
    by DC Sullivan
    posted to imaging oncology review by xtizon on 2007-10-31 17:38:06 as ****
  • Dynamic contrast-enhanced MRI in clinical oncology: Current status and future directions
    Journal of Magnetic Resonance Imaging, Vol. 16, No. 4. (2002), pp. 407-422.
    by Anwar R Padhani
    posted to dce-mri oncology by xtizon on 2006-07-21 09:45:13 as ***** along with 3 people JanLesniak claudiacalcagno anitabanerji
  • Imaging and Oncologic Drug Development
    J Clin Oncol, Vol. 24, No. 20. (10 July 2006), pp. 3261-3273.
    by Wafik S El-Deiry, Caroline C Sigman, Gary J Kelloff
    posted to imaging oncology review by xtizon on 2008-02-12 08:17:25 as ****
  • Whole body MR imaging: Applications in oncology
    European Journal of Surgical Oncology, Vol. 32, No. 3. (April 2006), pp. 239-246.
    by C Johnston, S Brennan, S Ford, S Eustace
    posted to mri oncology whole-body by xtizon on 2007-02-16 08:17:35 as ** along with 1 person Lara
  • Positron Emission Tomography Measurement of Tumor Metabolism and Growth: Its Expanding Role in Oncology
    Molecular Imaging and Biology, Vol. 8, No. 3. (1 May 2006), pp. 141-150.
    by Anthony Shields
    posted to cancer oncology pet review by xtizon on 2007-07-25 15:35:35 as ****
  • Susceptibility-weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses
    Journal of Magnetic Resonance Imaging, Vol. 24, No. 1. (2006), pp. 41-51.
    by Vivek Sehgal, Zachary Delproposto, Djamel Haddar, Mark E Haacke, Andrew E Sloan, Lucia J Zamorano, Geoffery Barger, Jiani Hu, Yingbiao Xu, Karthik P Prabhakaran, Ilaya R Elangovan, Jaladhar Neelavalli, Jürgen R Reichenbach
    posted to mri oncology swi by xtizon on 2006-07-21 09:47:00 as ****
  • Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis - Correlation with biopsy and histopathology
    Journal of Magnetic Resonance Imaging, Vol. 24, No. 1. (2006), pp. 108-113.
    by Piotr Kozlowski, Silvia D Chang, Edward C Jones, Kenneth W Berean, Henry Chen, Larry S Goldenberg
    posted to dce-mri dw-mri oncology prostate by xtizon on 2006-07-21 09:48:09 as ***** along with 1 person decraene
  • Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRI
    Magnetic Resonance Imaging, Vol. 24, No. 6. (July 2006), pp. 721-725.
    by Guang Jia, Johannes T Heverhagen, Hannes Henry, Hans Polzer, Klaus T Baudendistel, Hendrik von Tengg-Kobligk, Andrea L Levine, Thomas J Rosol, Michael V Knopp
    posted to dce-mri oncology prostate by xtizon on 2006-07-21 09:51:30 as *****
  • Knowledge editing and maintenance tools for a semantic portal in oncology
    Int. J. Hum.-Comput. Stud., Vol. 62, No. 5. (May 2005), pp. 619-638.
    by Mathieu D'aquin, Christophe Bouthier, S&\#233;bastien Brachais, Jean Lieber, Amedeo Napoli
    posted to semanticweb semanticportal protege oncology knowledgemanagement by xcv on 2007-01-25 09:00:45 as read along with 1 person richy
  • The Medicare Prescription Drug Improvement and Modernization Act and the delivery of cancer chemotherapy.
    Am J Health Syst Pharm, Vol. 64, No. 15 Suppl 10. (1 August 2007)
    by C Downs
    posted to bm medicare medicare_part_d oncology by worx11 on 2007-09-20 20:17:29 as ** along with 1 group XROWXR
  • Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
    Health Technol Assess, Vol. 8, No. 28. (July 2004)
    by K Dalziel, A Round, K Stein, R Garside, A Price
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:27:43 as ** along with 1 group XROWXR
  • Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Clin Ther, Vol. 26, No. 11. (November 2004), pp. 1924-1933.
    by E Warren, S Ward, A Gordois, P Scuffham
    posted to bm cost-utility oncology outcomes by worx11 on 2007-09-20 19:25:17 as ** along with 1 group XROWXR
  • Formulary issues at a pediatric hospital: experience at Children's National Medical Center.
    Hosp Formul, Vol. 26, No. 6. (June 1991), pp. 500-510.
    by GJ Cohen, SJ Allen
    posted to bm formulary oncology outcomes by worx11 on 2007-09-20 20:14:23 as ** along with 1 group XROWXR
  • Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
    Support Care Cancer, Vol. 13, No. 12. (December 2005), pp. 975-986.
    by E De Cock, J Hutton, P Canney, JJ Body, P Barrett-Lee, MP Neary, G Lewis
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 20:21:31 as ** along with 1 group XROWXR
  • Cost considerations in the management of cancer in the older patient.
    Oncology (Williston Park), Vol. 21, No. 7. (June 2007)
    by JM McKoy, KA Fitzner, BJ Edwards, M Alkhatib, CC Tigue, NJ Nonzee, CR Bolden, CL Bennett
    posted to bm oncology outcomes by worx11 on 2007-09-20 18:54:02 as ** along with 1 group XROWXR
  • Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
    Breast, Vol. 16, No. 3. (June 2007), pp. 252-261.
    by C Skedgel, D Rayson, R Dewar, T Younis
    posted to bm cost-utility oncology outcomes by worx11 on 2007-09-20 19:02:57 as ** along with 1 group XROWXR
  • Challenges and recommendations for advancing the state-of-the-science of quality of life assessment in symptom management trials.
    Cancer, Vol. 110, No. 7. (20 August 2007), pp. 1621-1628.
    by David R R Buchanan, Ann M M O'mara, Joseph W W Kelaghan, Maria Sgambati, Worta McCaskill-Stevens, Lori Minasian
    posted to bm oncology quality quality_of_life by worx11 on 2007-09-21 17:19:50 as ** along with 1 person and 1 group suizan XROWXR
  • Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
    Am J Clin Oncol, Vol. 26, No. 3. (June 2003), pp. 289-296.
    by G Dranitsaris, S Verma, M Trudeau
    posted to bm cost-utility oncology by worx11 on 2007-09-20 19:15:12 as ** along with 1 group XROWXR
  • Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
    Clin Breast Cancer, Vol. 7, No. 8. (June 2007), pp. 608-618.
    by TE Delea, J Karnon, O Sofrygin, SK Thomas, NL Papo, V Barghout
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:18:02 as ** along with 1 group XROWXR
  • European perspective on the costs and cost-effectiveness of cancer therapies.
    J Clin Oncol, Vol. 25, No. 2. (10 January 2007), pp. 191-195.
    by MF Drummond, AR Mason
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 20:08:00 as ** along with 1 group XROWXR
  • Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.
    Clin Drug Investig, Vol. 27, No. 2. (2007), pp. 85-93.
    by DM Huse, M von Mehren, G Lenhart, H Joensuu, C Blanke, W Feng, S Finkelstein, G Demetri
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:21:12 as ** along with 1 person and 1 group Terkko XROWXR
  • Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.
    Pharmacoeconomics, Vol. 23, No. 5. (2005), pp. 515-526.
    by K Dalziel, A Round, R Garside, K Stein
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:27:07 as ** along with 1 group XROWXR
  • Reimbursement for cancer treatment: coverage of off-label drug indications.
    J Clin Oncol, Vol. 24, No. 19. (1 July 2006), pp. 3206-3208.
    by
    posted to bm oncology by worx11 on 2007-09-20 18:57:10 as ** along with 1 group XROWXR
  • Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Clin Ther, Vol. 26, No. 9. (September 2004), pp. 1546-1561.
    by M Marchetti, M Caruggi, G Colombo
    posted to bm budget_impact cost-utility oncology outcomes by worx11 on 2007-09-20 19:23:02 as ** along with 1 group XROWXR
  • Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    J Clin Oncol, Vol. 25, No. 18. (20 June 2007)
    by E Low,
    posted to bm oncology outcomes by worx11 on 2007-09-20 20:11:50 as ** along with 1 group XROWXR
  • Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    Clin Ther, Vol. 27, No. 8. (August 2005), pp. 1295-1310.
    by E De Cock, J Hutton, P Canney, JJ Body, P Barrett-Lee, MP Neary, G Lewis
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 20:23:29 as ** along with 1 group XROWXR
  • Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.
    Pharmacoeconomics, Vol. 24, No. 3. (2006), pp. 237-250.
    by J Karnon, T Delea, SR Johnston, R Smith, J Brandman, J Sung, PE Goss
    posted to bm cost-effectiveness oncology outcomes by worx11 on 2007-09-20 19:16:06 as ** along with 1 group XROWXR
  • Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia.
    Br J Cancer, Vol. 89, No. 4. (18 August 2003), pp. 634-640.
    by A Gordois, P Scuffham, E Warren, S Ward
    posted to bm cost-utility oncology outcomes by worx11 on 2007-09-20 19:30:11 as ** along with 1 group XROWXR
  • International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency.
    Eur J Cancer, Vol. 43, No. 1. (January 2007), pp. 14-34.
    by SM Lichtman, H Wildiers, V Launay-Vacher, C Steer, E Chatelut, M Aapro
    posted to cancer ckd geriatric insufficiency launay-vacher oncology renal by vlv75 on 2007-12-11 00:15:32 as read
  • Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations.
    Ann Oncol, Vol. 18, No. 8. (August 2007), pp. 1314-1321.
    by V Launay-Vacher, E Chatelut, SM Lichtman, H Wildiers, C Steer, M Aapro,
    posted to ckd geriatric insufficiency launay-vacher oncology renal siog by vlv75 on 2007-12-11 00:15:08 as read
  • Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.
    Cancer chemotherapy and pharmacology, Vol. 61, No. 6. (May 2008), pp. 903-909.
    by Vincent Launay-Vacher, Jean-Baptiste B Rey, Corinne Isnard-Bagnis, Gilbert Deray, Mikael Daouphars
    posted to cancer insufficiency oncology renal by vlv75 on 2008-07-03 08:13:46 as read along with 1 person jyuh
  • History of psycho-oncology: overcoming attitudinal and conceptual barriers
    Psychosomatic Medicine, Vol. 64, No. 2., pp. 206-221.
    by Jimmie C Holland
    posted to multidisciplinary oncology by suizan on 2007-11-14 21:34:12 as ** along with 1 person and 1 group 1903projects 801
  • Gastric cancer: new genetic developments.
    J Surg Oncol, Vol. 90, No. 3. (1 June 2005)
    by HT Lynch, W Grady, G Suriano, D Huntsman
    posted to gastrology oncology by siro on 2005-12-05 14:02:50 as **
  • Simple formula for the surface area of the body and a simple model for anthropometry
    Clinical Anatomy, Vol. 18, No. 2. (4 February 2005), pp. 126-130.
    by Bruce D Reading, Brian Freeman
    posted to bsa cwpbok oncology by siro on 2005-03-21 02:23:44 as ** along with 1 person lwilliams
  • Is herpes zoster a marker for occult or subsequent malignancy?
    Br J Gen Pract, Vol. 55, No. 511. (February 2005), pp. 102-107.
    by F Buntinx, R Wachana, S Bartholomeeusen, K Sweldens, H Geys
    posted to oncology by siro on 2005-04-30 04:39:09 as **
  • Acne in Adolescence and Cause-specific Mortality: Lower Coronary Heart Disease but Higher Prostate Cancer Mortality: The Glasgow Alumni Cohort Study.
    Am J Epidemiol, Vol. 161, No. 12. (15 June 2005), pp. 1094-1101.
    by B Galobardes, GD Smith, M Jeffreys, S Kinra, P McCarron
    posted to acne atherosclerosis cardiology family_practice oncology by siro on 2005-06-20 07:56:52 as *****
  • Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer.
    Yonsei Med J, Vol. 46, No. 3. (30 June 2005), pp. 388-393.
    by JH Chung, MS Park, YS Kim, J Chang, JH Kim, SK Kim, SK Kim
    posted to metastasis oncology by siro on 2005-10-04 15:10:40 as read
  • Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population.
    J Gastroenterol Hepatol, Vol. 19, No. 2. (February 2004), pp. 182-186.
    by JE Kim, KT Lee, JK Lee, SW Paik, JC Rhee, KW Choi
    posted to family_practice oncology by siro on 2005-07-27 03:21:13 as **
  • Comparison of treatment volumes and techniques in prostate cancer radiation therapy.
    Am J Clin Oncol, Vol. 28, No. 6. (December 2005), pp. 618-625.
    by CT Lee, L Dong, AW Ahamad, H Choi, R Cheung, AK Lee, DF Horne, AJ Breaux, DA Kuban
    posted to oncology radiology urology by siro on 2005-12-06 02:25:34 as **
  • [Diagnostic mammography and sonography: concordance of the breast imaging reporting assessments and final clinical outcome]
    Rofo, Vol. 177, No. 11. (November 2005), pp. 1545-1551.
    by J Lorenzen, AK Wedel, BW Lisboa, T Löning, G Adam
    posted to breast oncology by siro on 2006-01-05 07:14:35 as **
  • Tamoxifen Treatment and New-Onset Depression in Breast Cancer Patients
    Psychosomatics, Vol. 48, No. 3. (1 June 2007), pp. 205-210.
    by Kelly C Lee, Thomas G Ray, Enid M Hunkeler, Patrick R Finley
    posted to clinical_trial major_depression obgyn oncology side_effect by pseudopharm on 2007-05-04 20:41:31 as ***
  • Adverse drug reactions in patients with phaeochromocytoma : incidence, prevention and management.
    Drug Saf, Vol. 30, No. 11. (2007), pp. 1031-1062.
    by G Eisenhofer, G Rivers, AL Rosas, Z Quezado, WM Manger, K Pacak
    posted to consult_liason oncology side_effect by pseudopharm on 2007-11-20 23:56:42 as ***
  • A 74-year-old Man With Chronic Lymphocytic Leukemia, Cough, and a Lung Mass*
    Chest, Vol. 116, No. 6. (1 December 1999), pp. 1798-1801.
    by Douglas Michaelsen, Marc A Judson
    posted to oncology pulmonary by pgogineni on 2007-10-16 15:06:54 as read
  • Interferon alpha 2b as maintenance therapy improves outcome in follicular lymphoma.
    Leuk Lymphoma, Vol. 45, No. 11. (November 2004), pp. 2247-2251.
    by A Avilés, N Neri, J Huerta-Guzmán, F Pérez, L Sotelo
    posted to gastroenterology ifnresearch oncology by pgogineni on 2005-02-18 16:26:31 as ***
  • Laser-driven proton oncology a unique new cancer therapy?
    British Journal of Radiology, Vol. 80, No. 959. (3 September 2007), pp. 855-858.
    by KWD Ledingham, W Galster, R Sauerbrey
    posted to beam electron ion laser oncology radiotherapy by michaelbussmann on 2008-04-23 18:20:20 as **
  • Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism
    PNAS, Vol. 103, No. 10. (7 March 2006), pp. 3799-3804.
    by Ayyakannu Ayyanan, Gianluca Civenni, Laura Ciarloni, Catherine Morel, Nathalie Mueller, Karine Lefort, Anna Mandinova, Wassim Raffoul, Maryse Fiche, Gian P Dotto, Cathrin Brisken
    posted to notch oncology pathway wnt by lhonigberg on 2006-03-08 16:22:25 as **
  • The mighty mouse: genetically engineered mouse models in cancer drug development
    Nature Reviews Drug Discovery, Vol. 5, No. 9. (18 August 2006), pp. 741-754.
    by Norman E Sharpless, Ronald A Depinho
    posted to oncology review technique by lhonigberg on 2006-10-22 01:05:15 as ****
  • A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
    Cancer Cell, Vol. 10, No. 6. (December 2006), pp. 515-527.
    by Richard M Neve, Koei Chin, Jane Fridlyand, Jennifer Yeh, Frederick L Baehner, Tea Fevr, Laura Clark, Nora Bayani, Jean-Philippe Coppe, Frances Tong
    posted to bioinformatics microarray oncology by lhonigberg on 2006-12-11 23:58:13 as ** along with 4 people jfr jayster4 jdiezperezj chrisamiller
  • A loss-of-function RNA interference screen for molecular targets in cancer
    Nature (29 March 2006)
    by Vu N Ngo, Eric R Davis, Laurence Lamy, Xin Yu, Hong Zhao, Georg Lenz, Lloyd T Lam, Sandeep Dave, Liming Yang, John Powell, Louis M Staudt
    posted to dlbcl oncology rnai screen by lhonigberg on 2006-04-01 18:51:42 as ** along with 3 people jfr tabu mhucka
    • 注: このページを引用する時は次のURLでどうぞ: http://www.citeulike.org/tag/oncology

    Result page: 1 2 3 Next RIS BibTeX
    CiteULike organises scholarly (or academic) papers or literature and provides bibliographic (which means it makes bibliographies) for universities and higher education establishments. It helps undergraduates and postgraduates. People studying for PhDs or in postdoctoral (postdoc) positions. The service is similar in scope to EndNote or RefWorks or any other reference manager like BibTeX, but it is a social bookmarking service for scientists and humanities researchers.